Genia Long

636 total citations
19 papers, 391 citations indexed

About

Genia Long is a scholar working on Economics and Econometrics, Immunology and General Health Professions. According to data from OpenAlex, Genia Long has authored 19 papers receiving a total of 391 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Economics and Econometrics, 5 papers in Immunology and 4 papers in General Health Professions. Recurrent topics in Genia Long's work include Health Systems, Economic Evaluations, Quality of Life (14 papers), Pharmaceutical Economics and Policy (14 papers) and Biosimilars and Bioanalytical Methods (5 papers). Genia Long is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (14 papers), Pharmaceutical Economics and Policy (14 papers) and Biosimilars and Bioanalytical Methods (5 papers). Genia Long collaborates with scholars based in United States, Singapore and China. Genia Long's co-authors include Henry G. Grabowski, Richard Mortimer, Iain Cockburn, Joseph A. DiMasi, David Cutler, Ernst R. Berndt, Alicia Sasser, Pierre Y. Crémieux, Andrée-Anne Fournier and Margaret Kyle and has published in prestigious journals such as Nature Reviews Drug Discovery, Health Affairs and Value in Health.

In The Last Decade

Genia Long

18 papers receiving 367 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Genia Long United States 9 294 93 66 56 50 19 391
Reed F. Beall Canada 15 387 1.3× 62 0.7× 116 1.8× 123 2.2× 45 0.9× 68 640
Pieter Dylst Belgium 13 505 1.7× 125 1.3× 45 0.7× 155 2.8× 119 2.4× 24 565
Anna Bucsics Austria 15 417 1.4× 37 0.4× 26 0.4× 106 1.9× 113 2.3× 28 566
Tomáš Tesař Slovakia 14 249 0.8× 89 1.0× 14 0.2× 53 0.9× 14 0.3× 49 440
Roberta Joppi Italy 10 326 1.1× 21 0.2× 22 0.3× 101 1.8× 59 1.2× 20 451
Gisbert Selke Germany 10 202 0.7× 40 0.4× 10 0.2× 68 1.2× 44 0.9× 20 765
Ott Laius Estonia 7 292 1.0× 32 0.3× 12 0.2× 86 1.5× 69 1.4× 23 396
Marija Kalaba Sweden 8 269 0.9× 36 0.4× 11 0.2× 62 1.1× 64 1.3× 10 418
Kristina Garuolienė Lithuania 10 407 1.4× 35 0.4× 12 0.2× 114 2.0× 94 1.9× 16 516
Neil McAuslane United Kingdom 15 447 1.5× 54 0.6× 15 0.2× 59 1.1× 76 1.5× 59 578

Countries citing papers authored by Genia Long

Since Specialization
Citations

This map shows the geographic impact of Genia Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Genia Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Genia Long more than expected).

Fields of papers citing papers by Genia Long

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Genia Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Genia Long. The network helps show where Genia Long may publish in the future.

Co-authorship network of co-authors of Genia Long

This figure shows the co-authorship network connecting the top 25 collaborators of Genia Long. A scholar is included among the top collaborators of Genia Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Genia Long. Genia Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Grabowski, Henry G. & Genia Long. (2024). Post-approval indications and clinical trials for cardiovascular drugs: some implications of the US Inflation Reduction Act. Journal of Medical Economics. 27(1). 463–472. 4 indexed citations
3.
Grabowski, Henry G., Joseph A. DiMasi, & Genia Long. (2024). Postapproval Innovation For Oncology Drugs And The Inflation Reduction Act. Health Affairs. 43(10). 1400–1409. 6 indexed citations
4.
Grabowski, Henry G., et al.. (2021). Continuing trends in U.S. brand-name and generic drug competition. Journal of Medical Economics. 24(1). 908–917. 14 indexed citations
5.
Long, Genia, et al.. (2021). Research on the Mechanism of the Influence of E-WOM Dispersion on Consumers Return Intention. Journal of Physics Conference Series. 1944(1). 12023–12023. 3 indexed citations
6.
Cutler, David, Noam Y. Kirson, & Genia Long. (2020). Financing Drug Innovation in the US: Current Framework and Emerging Challenges. PharmacoEconomics. 38(9). 905–911. 1 indexed citations
7.
Long, Genia. (2019). Federal government-interest patent disclosures for recent top-selling drugs. Journal of Medical Economics. 22(12). 1261–1267. 3 indexed citations
8.
Grabowski, Henry G., et al.. (2016). Updated trends in US brand-name and generic drug competition. Journal of Medical Economics. 19(9). 836–844. 52 indexed citations
9.
Grabowski, Henry G., Joseph A. DiMasi, & Genia Long. (2015). The Roles Of Patents And Research And Development Incentives In Biopharmaceutical Innovation. Health Affairs. 34(2). 302–310. 39 indexed citations
10.
Long, Genia, Richard Mortimer, & Geoffrey T. Sanzenbacher. (2014). Evolving provider payment models and patient access to innovative medical technology. Journal of Medical Economics. 17(12). 883–893. 6 indexed citations
11.
Kaltenboeck, Anna, Genia Long, Eleanor Hayes‐Larson, & Gilberto Lopes. (2013). Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies. Expert Review of Clinical Pharmacology. 6(6). 691–701. 5 indexed citations
12.
Grabowski, Henry G., Genia Long, & Richard Mortimer. (2013). Recent trends in brand-name and generic drug competition. Journal of Medical Economics. 17(3). 207–214. 49 indexed citations
13.
Grabowski, Henry G., Margaret Kyle, Richard Mortimer, Genia Long, & Noam Y. Kirson. (2011). Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act. Health Affairs. 30(11). 2157–2166. 25 indexed citations
14.
Grabowski, Henry G., Genia Long, & Richard Mortimer. (2011). Implementation of the biosimilar pathway: economic and policy issues.. PubMed. 41(2). 511–57. 16 indexed citations
15.
Grabowski, Henry G., Genia Long, & Richard Mortimer. (2010). Data exclusivity for biologics. Nature Reviews Drug Discovery. 10(1). 15–16. 11 indexed citations
16.
Cutler, David, Genia Long, Ernst R. Berndt, et al.. (2007). The Value Of Antihypertensive Drugs: A Perspective On Medical Innovation. Health Affairs. 26(1). 97–110. 90 indexed citations
17.
Long, Genia, David Cutler, & Ernst R. Berndt. (2007). Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA. European Heart Journal Supplements. 9(suppl_B). B19–B22. 4 indexed citations
18.
Long, Genia, David Cutler, Ernst R. Berndt, et al.. (2006). The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke and Myocardial Infarction in the United States. National Bureau of Economic Research. 2 indexed citations
19.
Grabowski, Henry G., Iain Cockburn, & Genia Long. (2006). The Market For Follow-On Biologics: How Will It Evolve?. Health Affairs. 25(5). 1291–1301. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reed F. Beall Breakdown of academic impact, for papers by Pieter Dylst Breakdown of academic impact, for papers by Anna Bucsics Breakdown of academic impact, for papers by Tomáš Tesař Breakdown of academic impact, for papers by Roberta Joppi Breakdown of academic impact, for papers by Gisbert Selke Breakdown of academic impact, for papers by Ott Laius Breakdown of academic impact, for papers by Marija Kalaba Breakdown of academic impact, for papers by Kristina Garuolienė Breakdown of academic impact, for papers by Neil McAuslane
Rankless by CCL
2026